We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
-2.44%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$1.01B
AUM Growth
-$402M
Cap. Flow
-$269M
Cap. Flow %
-26.61%
Top 10 Hldgs %
65.73%
Holding
37
New
7
Increased
7
Reduced
12
Closed
7

Top Buys

Rank Stock Value
1
TNDM icon
Tandem Diabetes Care
TNDM
+$65.3M
2
GMED icon
Globus Medical
GMED
+$62.5M
3
ALGN icon
Align Technology
ALGN
+$62.2M
4
ARQL
Arqule Inc
ARQL
+$37.2M
5
STAA icon
STAAR Surgical
STAA
+$22.6M

Top Sells

Rank Stock Value
1
PCRX icon
Pacira BioSciences
PCRX
+$122M
2
IOVA icon
Iovance Biotherapeutics
IOVA
+$92.3M
3
URGN icon
UroGen Pharma
URGN
+$51.5M
4
VNDA icon
Vanda Pharmaceuticals
VNDA
+$51.1M
5
AERI
Aerie Pharmaceuticals
AERI
+$44.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SVRA icon
26
Savara
SVRA
$1.12B
$4.16M 0.41%
1,568,002
– –
SRPT icon
27
Sarepta Therapeutics
SRPT
$1.57B
$904K 0.09%
+12,000
New +$1.42M
QTTB icon
28
Q32 Bio
QTTB
$466M
$734K 0.07%
2,253
+800
+55% +$272K
IMMU
29
DELISTED
Immunomedics Inc
IMMU
$597K 0.06%
45,000
-100,000
-69% -$1.47M
ITCI
30
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$149K 0.01%
+20,000
New +$192K
CORT icon
31
Corcept Therapeutics
CORT
$12.4B
– –
-2,882,773
Closed -$32.1M
INSM icon
32
Insmed
INSM
$21.4B
– –
-1,711,150
Closed -$43.8M
PCRX icon
33
Pacira BioSciences
PCRX
$1.04B
– –
-2,799,916
Closed -$122M
URGN icon
34
UroGen Pharma
URGN
$1.86B
– –
-1,433,774
Closed -$51.5M
VNDA icon
35
Vanda Pharmaceuticals
VNDA
$307M
– –
-3,626,545
Closed -$51.1M
ICPT
36
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-388,470
Closed -$30.9M
AERI
37
DELISTED
Aerie Pharmaceuticals
AERI
– –
-1,506,695
Closed -$44.5M
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q3 2019 Portfolio in Review

As of Q3 2019, Consonance Capital Management held 37 positions worth $1.01B, down 28% from $1.41B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Consonance Capital Management withdrew a net $269M in Q3 2019, closing 7 positions and reducing 12 holdings. Its most notable exit was Pacira BioSciences, an estimated $122M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 96% a quarter earlier.

Against the trend, Consonance Capital Management opened a new position in Tandem Diabetes Care worth $60.3M.

  • Consonance Capital Management's largest Q3 2019 buy was Tandem Diabetes Care: 1,022,257 shares worth $60.3M.
  • Consonance Capital Management added most to Arqule Inc in Q3 2019, an estimated $37.2M increase.
  • Consonance Capital Management's biggest Q3 2019 reduction was Iovance Biotherapeutics, cutting an estimated $92.3M.
  • Consonance Capital Management fully exited Pacira BioSciences in Q3 2019, selling an estimated $122M.
  • Consonance Capital Management's ten largest holdings make up 66% of its $1.01B portfolio in Q3 2019.
  • Consonance Capital Management opened 7 new positions and closed 7 in Q3 2019.
  • Consonance Capital Management's portfolio value fell 28% quarter-over-quarter to $1.01B.

Based on Consonance Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.